RxDoctor Payments Data

Reem Jarbou, DO

Gastroenterology · Rochester Hills, MINPI 1578825857

Payments from drug & device makers

$12,101in general payments, 2019–2025

Across 531 payments — averaging $22.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$3K
  • Takeda Pharmaceuticals U.S.A., Inc.$1K
  • Johnson & Johnson$917
  • Pfizer$707
  • Janssen Scientific Affairs, LLC$418
  • plus $4K from 32 others

What the payments were for

  • Food & beverage$12,101100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,101 in reported general payments places this provider in the 75th percentile of 497 gastroenterology providers in Michigan.

See all gastroenterology providers in Michigan

Medicare billing

Part B allowed, 2024
$301,445
Medicare patients
811
Services billed
2,807

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XifaxanRifaximin55$134,744
LinzessLinaclotide107$67,296
GimotiMetoclopramide Hcl12$22,966
TrulancePlecanatide24$14,009
CholestyramineCholestyramine (With Sugar)47$5,245
Sucralfate236$4,679
Omeprazole328$3,654
Pantoprazole Sodium252$3,532
Famotidine273$2,058
Cholestyramine LightCholestyramine11$1,498
Dicyclomine Hcl117$1,360
Esomeprazole Magnesium22$594
Lactulose36$567
LoperamideLoperamide Hcl20$402
Hydrocortisone20$302

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan, Trulance$2,564$148,75379 claims
AbbVieLinzess$2,806$67,296107 claims
Evoke Pharma, Inc.Gimoti$23$22,96612 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 497 gastroenterology providers in Michigan.

Other gastroenterology in Rochester Hills

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →